


PERSONAL INFORMATION**Luca Boni**

Vico Vegetti, 7 int 2 – 16123 – Genoa – Italy

+39.010.555.8476 +39.347.855.24.62

luca.boni@hsanmartino.it

Sex Male | Date of birth 11/01/1958 | Nationality Italian

Enterprise	University	EPR
<input checked="" type="checkbox"/> Management Level	<input type="checkbox"/> Full professor	<input type="checkbox"/> Research Director and 1st level Technologist / First Researcher and 2nd level Technologist
<input type="checkbox"/> Mid-Management Level	<input type="checkbox"/> Associate Professor	<input type="checkbox"/> Level III Researcher and Technologist
<input type="checkbox"/> Employee / worker level	<input type="checkbox"/> Researcher and Technologist of IV, V, VI and VII level / Technical collaborator	<input type="checkbox"/> Researcher and Technologist of IV, V, VI and VII level / Technical collaborator

WORK EXPERIENCE

From March, 2020 to present

Head of Clinical Epidemiology Unit

Senior Biostatistician and Regulatory Affairs Expert

IRCCS Ospedale Policlinico San Martino, Genoa, Italy

www.ospedalesanmartino.it

- Manage the annual economical budget and promote the fundraising task
- Provide statistical leadership for clinical trials and observational studies
- Give an operative support for the planning, conducting and statistical analysis of results of investigator-initiated clinical trials and observational studies
- Guarantee the quality of data and statistical integrity of the clinical studies
- Promote the partnership with other Institutions or Cooperative Research Groups
- Communicate results to non-statistical audience
- Contribute to the scientific paper writing process
- Facilitate the spread of the knowledge about clinical epidemiology methodologies
- Represent a consulting reference point for the Institutional Scientific Board, in matter of clinical research
- Collaborate with the Regional Health System for facilitating the spread of research activities within the Public Institutions and promoting operative synergisms with the Drug Companies

Business or sector: Clinical epidemiology

From November, 2017 to February, 2020

Head of Clinical Trial Center

Senior Biostatistician and Regulatory Affairs Expert

Azienda Ospedaliero-Universitaria Careggi, Florence, Italy

- Manage the annual economical budget
- Provide statistical leadership for clinical trials and observational studies
- Give an operative support for the planning, conducting and statistical analysis of results of investigator-initiated clinical trials and observational studies
- Guarantee the quality of data and statistical integrity of the clinical studies
- Supervise the Clinical Research Administrators operating within the Institution and interacting with the Health Authorities
- Promote the partnership with other Institutions or Cooperative Research Groups
- Communicate results to non-statistical audience
- Contribute to the scientific paper writing process
- Facilitate the spread of the knowledge about clinical epidemiology methodologies

- Collaborate with the Regional Health System for facilitating the spread of research activities within the Public Institutions and promoting operative synergisms with the Drug Companies

Business or sector: Clinical research

From September, 2008 to
October, 2017

Head of Clinical Trials Coordinating Center of Istituto Toscano Tumori (ITT)

Senior Biostatistician

Coordinator of the Scientific Committee of the Institutional Review Board of Azienda

Ospedaliero-Universitaria Careggi, Florence

President of the Patent Office

Visiting professor at the University of Florence

Azienda Ospedaliero-Universitaria Careggi, Florence, Italy

- Provide statistical leadership for clinical trials and observational studies
- Give an operative support for the planning, conducting and statistical analysis of results of investigator-initiated clinical trials and observational studies
- Guarantee the quality of data and statistical integrity of the clinical studies
- Promote the partnership between the ITT network and other Institutions or Cooperative Research Groups
- Supervise the Clinical Research Administrators operating within the ITT network and interacting with the Health Authorities
- Supervise the Statisticians operating within the ITT network
- Supervise the Programmers during the clinical database design process
- Communicate results to non-statistical audience
- Contribute to the scientific paper writing process
- Facilitate the spread of the knowledge about clinical epidemiology methodologies
- Represent a consulting reference point for the Scientific Board of ITT, in matter of clinical research
- Collaborate with the Regional Health System for facilitating the spread of research activities within the Public Institutions and promoting operative synergisms with the Drug Companies
- Manage the annual economical budget and promote the fundraising task

Business or sector: Clinical research

From July, 2003 to August, 2008

Head of Clinical Trials Unit of Istituto Nazionale per la Ricerca sul Cancro (IST)

Senior Biostatistician

Member of the Scientific Review Board of IST, Genoa

Istituto Nazionale per la Ricerca sul Cancro di Genova, Genoa, Italy

- Provide statistical leadership for clinical trials and observational studies
- Promote the collaboration between the investigators of the Institute and the Drug Companies
- Give an operative support for the planning, conducting and statistical analysis of results of investigator-initiated clinical trials and observational studies
- Guarantee the quality of data and statistical integrity of the clinical studies
- Supervise the Data Managers operating within the Unit
- Supervise the Programmers during the clinical database design process
- Communicate results to non-statistical audience
- Contribute to the scientific paper writing process
- Manage the annual economical budget and promote the fundraising task

Business or sector: Clinical research

EDUCATION AND TRAINING

July, 2003 Postgraduate degree in Biostatistics

Università degli Studi di Milano, Milan, Italy

- Clinical studies design

- Statistical analysis of clinical data

October, 1993 **Degree in Medicine and Surgery**
 Università degli Studi di Genova, Genoa, Italy

PERSONAL SKILLS

Mother tongue(s) Italian

Other language(s) English, B1

- | | |
|--------------------|---|
| Job-related skills | <ul style="list-style-type: none"> ▪ Leadership ▪ Sense of organisation ▪ Good communication skills ▪ Good experience in project or team management ▪ Excellent analytical skills and strong attention to details ▪ Good abilities for synthetic and global views over concrete situations ▪ Problem-solving attitude ▪ Ability to establish and maintain good working relations with people of different national and cultural backgrounds |
| Digital skills | <ul style="list-style-type: none"> ▪ Excellent computer proficiency ▪ Editing: MS Word, MS PowerPoint, MS Excel ▪ Databases: MS Access, MSSql, MySql ▪ Statistical packages: SAS, R, Stata, SPSS, BMDP, S-Plus, GLIM, Epicure ▪ Programming languages: php, JavaScript, Html, Basic, Pascal ▪ Development of web-based applications |

ADDITIONAL INFORMATION

Publications Long-Term Outcomes with Pharmacological Ovarian Suppression during Chemotherapy in Premenopausal Early Breast Cancer Patients.

Lambertini M, Boni L, Michelotti A, Magnolfi E, Cogoni AA, Mosconi AM, Giordano M, Garrone O, Arpino G, Poggio F, Cinacchi P, Bighin C, Fregatti P, Pronzato P, Blondeaux E, Del Mastro L; GIM study group.

J Natl Cancer Inst. 2021 Nov 25. doi: 10.1093/jnci/djab213.

I.F. 13.506

Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial.

Pinto C, Zucali PA, Pagano M, Grossi F, Pasello G, Garassino MC, Tiseo M, Soto Parra H, Grossi F, Cappuzzo F, de Marinis F, Pedrazzoli P, Bonomi M, Gianoncelli L, Perrino M, Santoro A, Zanelli F, Bonelli C, Maconi A, Frega S, Gervasi E, Boni L, Ceresoli GL.

Lancet Oncol. 2021 Oct;22(10):1438-1447. doi: 10.1016/S1470-2045(21)00404-6.

I.F. 41.316

Effect modifiers of low dose tamoxifen in a randomized trial in breast non-invasive disease.

De Censi A, Puntoni M, Johansson H, Guerreri-Gonzaga A, Caviglia S, Avino F, Cortesi L, Ponti A, Pacquola MG, Falcini F, Gulisano M, Digennaro M, Cariello A, Cagossi K, Pinotti G, Lazzeroni M, Serrano D, Briata IM, Buttiron Webber T, Boni L, Bonanni B

Clin Cancer Res. 2021 Feb 19;clincanres.4213.2020. doi: 10.1158/1078-0432.CCR-20-4213. Online ahead of print.

I.F. 10.107

Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic

colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial.
 Cremolini C, Antoniotti C, Rossini D, Lonardi S, Loupakis F, Pietrantonio F, Bordonaro R, Latiano TP, Tamburini E, Santini D, Passardi A, Marmorino F, Grande R, Aprile G, Zaniboni A, Murgioni S, Granetto C, Buonadonna A, Moretto R, Corallo S, Cordio S, Antonuzzo L, Tomasello G, Masi G, Ronzoni M, Di Donato S, Carlonagno C, Clavarezza M, Ritoro G, Mambrini A, Roselli M, Cupini S, Mammoliti S, Fenocchio E, Corgna E, Zagonel V, Fontanini G, Ugolini C, Boni L, Falcone A; GONO Foundation Investigators.

Lancet Oncol. 2020 Apr;21(4):497-507. doi: 10.1016/S1470-2045(19)30862-9. Epub 2020 Mar 9.
 I.F. 33.752

Muscular Mitral-Aortic Discontinuity: a Congenital Defect Identified in Patients with Obstructive Hypertrophic Cardiomyopathy

Ferrazzi P, Spirito P, Binaco I, Zyrianov A, Poggio D, Vaccari G, Grillo M, Pezzoli L, Scatigno A, Dorobantu L, Mortara A, Bruzzi P, Boni L, Iascone M
 JACC, In press
 I.F. 18.639

Lung recruitment before surfactant administration in extremely preterm neonates with respiratory distress syndrome (IN-REC-SUR-E): a randomised, unblinded, controlled trial.

Vento G, Ventura ML, Pastorino R, van Kaam AH, Carnielli V, Cools F, Dani C, Mosca F, Polglase G, Tagliabue P, Boni L, Cota F, Tana M, Tirone C, Aurilia C, Lio A, Costa S, D'Andrea V, Luente M, Nigro G, Giordano L, Roma V, Villani PE, Fusco FP, Fasolato V, Colnaghi MR, Matassa PG, Vendettuoli V, Poggi C, Del Vecchio A, Petrillo F, Bettà P, Mattia C, Garani G, Solinas A, Gitto E, Salvo V, Gargano G, Balestri E, Sandri F, Mescoli G, Martinelli S, Ilardi L, Ciarmoli E, Di Fabio S, Maranella E, Grassia C, Ausanio G, Rossi V, Molta A, Tina LG, Maiolo K, Nobile S, Messner H, Staffler A, Ferrero F, Stasi I, Pieragostini L, Mondello I, Haass C, Consigli C, Vedovato S, Grison A, Maffei G, Presta G, Pemiola R, Vitaliti M, Re MP, De Curtis M, Cardilli V, Lago P, Tormena F, Orfeo L, Gizzi C, Massenzi L, Gazzolo D, Strozzi MCM, Bottino R, Pontiggia F, Berardi A, Guidotti I, Cacace C, Meli V, Quartulli L, Scromano A, Casati A, Grappone L, Pillow JJ.

Lancet Respir Med. 2020 Jul 17:S2213-2600(20)30179-X. doi: 10.1016/S2213-2600(20)30179-X.
 I.F. 25.094

Randomized Placebo Controlled Trial of Low-Dose Tamoxifen to Prevent Local and Contralateral Recurrence in Breast Intraepithelial Neoplasia

De Censi A, Puntoni M, Guerreri-Gonzaga A, Caviglia S, Avino F, Cortesi L, Taveritti C, Pacquola MG, Falcini F, Gulisano M, Digennaro M, Cariello A, Cagossi K, Pinotti G, Lazzeroni M, Serrano D, Branchi D, Campora S, Petrella M, Buttiron Webber T, Boni L, Bonanni B
 J Clin Oncol. 2019 Apr 11:JCO1801779. doi: 10.1200/JCO.18.01779
 I.F. 26.360

Cremolini C, Antoniotti C, Lonardi S, Bergamo F, Cortesi E, Tomasello G, Moretto R, Ronzoni M, Racca P, Loupakis F, Zaniboni A, Tonini G, Buonadonna A, Marmorino F, Allegrini G, Granetto C, Masi G, Zagonel V, Sensi E, Fontanini G, Boni L, Falcone A
 Primary Tumor Sidedness and Benefit from FOLFOXIRI plus Bevacizumab as Initial Therapy for Metastatic Colorectal Cancer
 Ann Oncol. 2018 Apr 20. doi: 10.1093/annonc/mdy140
 I.F. 32.976

Malomi L, Curigliano G, Minisini AM, Cinieri S, Tondini CA, D'Hollander K, Arpino G, Bernardo A, Martignetti A, Criscitiello C, Puglisi F, Pestrin M, Sanna G, Moretti E, Risi E, Biagioni C, McCartney A, Boni L, Buyse M, Migliaccio I, Biganzoli L, Di Leo A
 Palbociclib as single agent or in combination with the endocrine therapy received before disease progression for estrogen receptor-positive, HER2-negative metastatic breast cancer: TREnd trial
 Ann Oncol. 2018 Aug 1;29(8):1748-1754. doi: 10.1093/annonc/mdy214
 I.F. 32.976

Lambertini M, Moore HCF, Leonard RCF, Loibl S, Munster P, Bruzzone M, Boni L, Unger JM, Anderson RA, Mehta K, Minton S, Poggio F, Albain KS, Adamson DJA, Gerber B, Cripps A, Bertelli G, Seiler S, Ceppi M, Partridge AH, Del Mastro L
 Gonadotropin-Releasing Hormone Agonists During Chemotherapy for Preservation of Ovarian Function and Fertility in Premenopausal Patients With Early Breast Cancer: A Systematic Review and Meta-Analysis of Individual Patient-Level Data
 J Clin Oncol. 2018 May 2:JCO2018780858. doi: 10.1200/JCO.2018.78.0858.
 I.F. 24.008

Cremolini C, Antoniotti C, Lonardi S, Aprile G, Bergamo F, Masi G, Grande R, Tonini G, Mescoli C, Cardellino GG, Coltellini L, Salvatore L, Corsi DC, Lupi C, Gemma D, Ronzoni M, Dell'Aquila E, Marmorino F, Di Fabio F, Mancini ML, Marcucci L, Fontanini G, Zagonel V, Boni L, Falcone A

Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for RAS and BRAF Wild-type Metastatic Colorectal Cancer: A Randomized Phase 2 Clinical Trial.

JAMA Oncol. 2018 Feb 15. doi: 10.1001/jamaoncol.2017.5314

I.F. 31.777

Dell'Aquila E, Cremolini C, Zeppola T, Lonardi S, Bergamo F, Masi G, Stellato M, Marmorino F, Schirripa M, Urbano F, Ronzoni M, Tomasello G, Zaniboni A, Racca P, Buonadonna A, Allegrini G, Fea E, Di Donato S, Chiara S, Tonini G, Tomcikova D, Boni L, Falcone A, Santini D

Prognostic and predictive role of neutrophil/lymphocytes ratio in metastatic colorectal cancer: a retrospective analysis of the TRIBE study by GONO.

Ann Oncol. 2018 Jan 8. doi: 10.1093/annonc/mdy004

I.F. 32.976

Tiseo M, Boni L, Ambrosio F, Camerini A, Baldini E, Cinieri S, Brighenti M, Zanelli F, Defraia E, Chiari R, Dazzi C, Tibaldi C, Turolla GM, D'Alessandro V, Zilembo N, Trolesi AR, Grossi F, Riccardi F, Ardizzoni A

Italian, Multicenter, Phase III, Randomized Study of Cisplatin Plus Etoposide With or Without Bevacizumab as First-Line Treatment in Extensive-Disease Small-Cell Lung Cancer: The GOIRC-AIFA FARM6PMFJM Trial.

J Clin Oncol. 2017 Apr 20;35(12):1281-1287. doi: 10.1200/JCO.2016.69.4844

I.F. 24.008

Cremolini C, Loupakis F, Masi G, Lonardi S, Granetto C, Mancini ML, Chiara S, Moretto R, Rossini D, Vitello S, Allegrini G, Tonini G, Bergamo F, Tomasello G, Ronzoni M, Buonadonna A, Bustreo S, Barbara C, Boni L, Falcone A,

FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: a propensity score-adjusted analysis from two randomized clinical trials.

Ann Oncol. 2016 Feb 9.

I.F. 11.855

Pemetrexed plus carboplatin versus pemetrexed in pretreated patients with advanced non-squamous non-small-cell lung cancer: treating the right patients based on individualized treatment effect prediction

Visseren FL, van Kruisjield RC, Boni L, Groen HJ, Dingemans AM, Aerts JG, van der Graaf Y, Ardizzoni A, Smit EF

Ann Oncol. 2016 Jul;27(7):1280-6. doi: 10.1093/annonc/mdw154.

I.F. 11.855

Lambertini M, Boni L, Michelotti A, Gamucci T, Scotto T, Gori S, Giordano M, Garrone O, Levaggi A, Poggio F, Giraudi S, Bighin C, Vecchio C, Sertoli MR, Pronzato P, Del Mastro L; GIM Study Group. Ovarian Suppression With Triptorelin During Adjuvant Breast Cancer Chemotherapy and Long-term Ovarian Function, Pregnancies, and Disease-Free Survival: A Randomized Clinical Trial.

JAMA. 2015 Dec 22-29;314(24):2632-40

I.F. 31.777

Cremolini C, Loupakis F, Antoniotti C, Lupi C, Sensi E, Lonardi S, Mezi S, Tomasello G, Ronzoni M, Zaniboni A, Tonini G, Carluomagno C, Allegrini G, Chiara S, D'Amico M, Granetto C, Cazzaniga M, Boni L, Fontanini G, Falcone A.

FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study.

Lancet Oncol. 2015 Aug 28

I.F. 41.316

Loupakis F, Cremolini C, Masi G, Lonardi S, Zagonel V, Salvatore L, Cortesi E, Tomasello G, Ronzoni M, Spadi R, Zaniboni A, Tonini G, Buonadonna A, Amoroso D, Chiara S, Carluomagno C, Boni C, Allegrini G, Boni L, Falcone A

Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.

N Engl J Med. 2014 Oct 23;371(17):1609-18

I.F. 55.873

Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial

Del Mastro L, Boni L, Michelotti A, Gamucci T, Olmeo N, Gori S, Giordano M, Garrone O, Pronzato P, Bighin C, Levaggi A, Giraudi S, Cresti N, Magnolfi E, Scotto T, Vecchio C, Venturini M

JAMA. 2011 Jul 20;306(3):269-76. doi: 10.1001/jama.2011.991

I.F. 30.026

15-FEB-2022
Ludovici